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Abstract
Aims/Hypothesis: Inhibition of PD1-PDL1 signaling in NOD mice accelerates onset of type 1 diabetes implicating this
pathway in suppressing the emergence of pancreatic beta cell reactive T-cells. However, the molecular mechanism by which
PD1 signaling protects from type 1 diabetes is not clear. We hypothesized that differential susceptibility of Idd mouse strains
to type 1 diabetes when challenged with anti PDL1 will identify genomic loci that collaborate with PD1 signaling in
suppressing type 1 diabetes.
Methods: Anti PDL1 was administered to NOD and various Idd mouse strains at 10 weeks of age and onset of disease was
monitored by measuring blood glucose levels. Additionally, histological evaluation of the pancreas was performed to
determine degree of insulitis. Statistical analysis of the data was performed using Log-Rank and Student’s t-test.
Results: Blockade of PDL1 rapidly precipitated type 1 diabetes in nearly all NOD Idd congenic strains tested, despite the fact
that all are moderately (Idd5, Idd3 and Idd10/18) or highly (Idd3/10/18 and Idd9) protected from spontaneous type 1 diabetes
by virtue of their protective Idd genes. Only the Idd3/5 strain, which is nearly 100% protected from spontaneous disease,
remained normoglycemic following PDL1 blockade.
Conclusions: These results indicate that multiple Idd loci collaborate with PD1 signaling. Anti PDL1 treatment undermines a
large portion of the genetic protection mediated by Idd genes in the NOD model of type 1 diabetes. Basal insulitis
correlated with higher susceptibility to type 1 diabetes. These findings have important implications since the PD1 pathway
is a target for immunotherapy.
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Introduction
Type 1 diabetes is a multi-factorial autoimmune disease
resulting from the destruction of pancreatic beta cells by
autoreactive T cells. Both environmental factors and variations
in multiple genetic loci have been implicated in the etiology of type
1 diabetes. The NOD mouse recapitulates many features of
human type 1 diabetes and is used extensively as an experimental
model.
Programmed death-1 (PD1) and its ligand PDL1 have been
shown to play an important role in regulating T cell activation and
peripheral tolerance. The PD1- PDL1 pathway is being explored
for developing therapies against recurrent solid tumors and
infectious diseases (such as HIV), since blocking the pathway
results in an increased immune response against tumors and
infections [1–3].
We and others have shown that PD1-PDL1 interaction is
critical for the regulation of CD4 and CD8 autoreactive T cells
involved in the development of type 1 diabetes [4,5]. Further,
while PD1 deficiency resulted in lupus-like symptoms in C57BL6
or BALB/c mice, it led to accelerated onset and frequency of type
1 diabetes in NOD mice [6].
In the NOD mouse model, blockade of PD1-PDL1 pathway
results in accelerated onset of autoimmune diabetes, raising
concern that immunotherapy by such blockade could increase
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susceptibility to autoimmune diseases, particularly in individuals
harboring susceptibility alleles. To date, numerous MHC-linked
and non-MHC-linked genes and genetic regions influencing the
susceptibility to autoimmune diseases have been identified in
humans, rats and mice. In insulin dependent type 1 diabetes, many
genes implicated in the control of glycemia have also been
described in the NOD Idd congenic mouse strains. Congenic NOD
strains have genetic loci from diabetes resistant parental strains
inserted (introgressed) into their genome (reviewed in [7]).
In recent years, NOD H2-Ag7 and H2-Enull MHC class II
genes have been unequivocally identified as susceptibility genes
within Idd1 [8]. Additionally, accumulated data support the
existence of particular susceptibility genes within other Idd regions.
Idd3 is the most well studied Idd region [9–11]. Protective alleles
in Idd3 reduce type 1 diabetes frequency and Il2 and Il21 are the
prime candidate genes. The protective effects of Idd3 are evident in
multiple cell types including antigen-presenting cells, effector T
cells and regulatory (FoxP3+) T cells which are critical for
maintaining immune cell homeostasis [12,13].
The prime gene candidate for Idd10 is Cd101 whose expression
on regulatory T cells and dendritic cells is affected in NOD/B6
polymorphisms [14]. Vav3, which encodes a guanine nucleotide
exchange factor important for signaling in immune cells, is the
only complete gene present in the 604 kb Idd18.1 region on
Chromosome 3. Gene expression evidence indicates that alter-
ation of Vav3 expression is an etiological factor in the development
of autoimmune beta-cell destruction in NOD mice, making it the
most likely candidate [15]. The Idd5 region is composed of at least
5 sub-regions. Idd5 contributes to islet-specific CD8 T cell
tolerance and to loss of CD4 tolerance through both lymphocytic
and non-lymphocytic compartments [9,16,17]. Candidate genes
for Idd5 sub regions include Ctla4 for Idd5.1 [18], Slc11a1 for Idd5.2
[19] and Acadl for Idd5.3 [20]. The Idd9 region on chromosome 4
is composed of at least three separate intervals, Idd9.1, Idd9.2, and
Idd9.3 and numerous candidate genes are present. Fine mapping
of type 1 diabetes regions Idd9.1 and Idd9.2 revealed further
genetic complexity [21]. The Idd9.1 sub-region has been shown to
influence regulatory T cells and iNKT cells [22,23]. Idd9.2 and
Idd9.3 have been linked to limit the expansion of islet specific
autoreactive CD8 T cells [24]. The Idd9.3 candidate gene encodes
4-1bb, which is important for CD4 and CD8 T cell activation
[25]. The Idd9 locus has also been previously described to play a
role in homing of islet-specific T cells [26]. Overall, Idd9 mice
display profound resistance to diabetes even though nearly all
develop insulitis.
In this study, we made use of four loci on Chromosome 3, four
on Chromosome 1, and three on Chromosome 4 to determine
which Idd regions conferring resistance to type 1 diabetes remain
so in the presence of anti PDL1 negative co-stimulatory blockade.
We show that blockade of the PD1-PDL1 interaction results in
accelerated onset of type 1 diabetes in all the NOD Idd strains
except NOD Idd3/5. Additionally, basal insulitis levels correlated
with higher susceptibility to type 1 diabetes induction by anti
PDL1 treatment.
Methods
Mice
Female NOD mice were obtained from Taconic (Germantown,
NY, USA). NOD congenics were obtained through the Taconic
Emerging Models program; NOD.B10-Idd9.1/9.2/9.3 (line 905)
[27], NOD.B10-Idd9.1 (line 1565) [22], NOD.B10-Idd9.2 (line
1566) [22], NOD.B10-Idd9.3 (line 1106) [22], NOD.B6-Idd10/18
(line 7754) [14,15,27–30], NOD.B10-Idd5.1 Idd5.2 Idd5.3 (line
1094) [31], NOD.B10-Idd5.1 (line 2193) [31], NOD.B10-Idd5.2
(line 6146) [31], NOD.B10-Idd5.3 (line 6360) [32], NOD.B6-Idd3/
10/18 (line 1538) [15,27], NOD.B6-Idd3 (line 1098) [12,27],
NOD.B6-Idd3 B10-Idd5 (line 6109) [27], NOD.B10-Idd5.2 Idd5.3
(line 1595) [32] and NOD.B10-Idd5.2 Idd5.3 Idd3 (lines 7380 and
9245, data combined in this study)[33]. The NOD congenic
strains will be referred to by their Idd numbers without adding
NOD before the designated Idd region. When referring to
congenic mice containing two or more Idd loci, the loci will be
separated by slashes. For example, Idd9.1 Idd9.2 Idd9.3 (line 905)
mice will be referred to as Idd9.1/9.2/9.3 for simplicity.
Spontaneous development of diabetes in females from these
strains of mice has been published (references noted above).
BDC2.5 TCR Tg mice were a gift of Drs. Diane Mathis and
Christophe Benoist [34]. NY8.3 mice were obtained from JDRF’s
Resource Sharing Program. All mouse experiments were approved
by the Institutional Animal Care and Use Committee of
Children’s Hospital Boston and University of Massachusetts
Medical School. All mice were cared for in accordance with
Boston Children’s Hospital and the University of Massachusetts
Medical School institutional guidelines.
Antibodies and Treatment Protocol
Anti mouse PDL1 mAb (MIH6, rat IgG2a) was generated as
previously described, [35] and was manufactured by BioXCell
(West Lebanon, NH, USA). Rat IgG (Sigma-Aldrich, St.Louis,
MO, USA) served as a control. Anti PDL1 was injected in PBS
i.p.; 500 mg on day 0, followed by 250 mg on days 2, 4, 6, 8, and 10
unless indicated otherwise. Mice were 10 weeks of age at the start
of treatment.
Monitoring for Diabetes
The onset of type 1 diabetes was defined as a random blood
glucose reading of 250 mg/dl or greater for three consecutive days.
Blood glucose levels were measured daily for the first two weeks
followed by 2–3 times per week by One Touch Ultra meter and
One Touch Ultra test strips (LifeScan, Milipitas, CA, USA).
Histology
Pancreases were fixed in 10% neutral buffered formalin in PBS
for 16 h and transferred to 70% ethanol before being embedded in
paraffin. Tissue sections were stained with H&E (Dana Farber
Cancer Institute’s Research Pathology Core, Boston, MA, USA)
and insulitis was graded by scoring a minimum of 10 islets per
mouse. Each mouse received a score from the average of graded
islets. Scores were defined as: 0 -no insulitis, 1 –peri-insulitis, 2,
50% insulitis, 3.50% insulitis, 4 -100% insulitis.
Adoptive transfer of BDC2.5 TCR-transgenic cells
Anti-CD25 mAb (clone 7D4, ATCC, Manassas, VA, USA) and
rabbit complement (Cedarlane, Burlington, NC, USA) were
incubated with splenocytes of BDC2.5 TCR Tg mice at 37uC
for 45 min to remove CD25+ cells (technique described in [36].
Remaining cells were labeled with 7.5 mM CFSE (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s instructions.
The percentage of CD4+ T cells in the splenocyte suspension was
determined by flow cytometry to calculate the volume needed for
injection of 0.56106 BDC2.5tg CD4+ T cells. Splenocytes were
labeled with CD3, CD4 and Vb4 antibodies and analyzed by flow
cytometry. Half a million CD4+ T cells were injected i.v. into the
tail veins of pre-diabetic 8–10 week old female NOD and age
matched Idd3/10/18 mice. Mice received 500 mg of either anti
PDL1 mAb or rat IgG one day before transfer (day 0), and 250 mg
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on days 2 and 4. Pancreatic LN and spleens were harvested on day
6 and cells were stained for CD4, Vb4 (KT4, BD Biosciences,
USA), labeled with CFSE and analyzed by flow cytometry.
Adoptive transfer of NY8.3 TCR transgenic cells
Splenocytes from NY8.3-NOD TCR Tg mice were used for
adoptive transfer studies. Splenocytes were enriched for CD8+ T
cells using the CD8+ T cell untouched isolation kit II (Miltenyi,
Auburn, CA, USA). One million CD8+ T cells were injected i.v.
into the tail veins of pre-diabetic 8–10 week old female NOD and
age matched Idd3/10/18 mice. The recipients received 500 mg of
either anti PDL1 mAb or IgG Ab one day before transfer (day 0),
and 250 mg on days 2 and 4. The pancreatic lymph node and
spleen were harvested on day 6 and the cells were acquired by flow
cytometry for CFSE labeling.
RNA extraction and Real time PCR of pancreas tissue
Pancreas tissue from Idd9 mice was stored in RNAlater solution
(Ambion, Austin, TX, USA) and total RNA was extracted using
the RNAeasy Mini kit (Qiagen, Gaithersburg, MD, USA). RNA
was redissolved in RNAse-free water and the yield quantified by
spectrophotometry. Equal amounts of RNA were used for
quantitative real time PCR. First strand cDNA synthesis was
performed using Superscript III (Invitrogen, Grand Island, NY,
USA). All reactions were run in triplicates in an ABI Prism 7300
(Applied Biosystems, Foster City, CA, USA) and normalized to
GAPDH. For a list of primers used, see Electronic Supplemental
Material.
Statistical Analysis
Kaplan-Meier survival analysis was performed to compare the
frequency of diabetes in sub-congenic strains using the Log-Rank
test. Differences in insulitis between congenic strains were
analyzed by unpaired two-tailed Student’s t test. A p value of ,
0.05 was considered significant.
Results
Diabetes-resistant NOD Idd strains develop diabetes
upon anti PDL1 treatment
In order to determine if blocking the PD1-PDL1 pathway would
induce autoimmune diabetes in mice genetically protected from
developing the disease, strains of mice protected from type 1
diabetes because they carry protective genes derived from B6 and
B10 mice, were treated with anti PDL1 mAb. We tested the
following 14 NOD congenic strains to examine the genetic
protection due to a range of genes and gene combinations which
can possibly contribute to resisting the precipitation of type 1
diabetes following PDL1 blockade: Idd3, Idd10/18, Idd3/10/18,
Idd5 (which includes the subcongenic regions of Idd5.1, Idd5.2, and
Idd5.3), Idd5.1, Idd5.2, Idd5.3, Idd5.2/5.3, Idd3/5, Idd3/5.2/5.3,
Idd9 (which includes the sub-congenic regions of Idd9.1, Idd9.2 and
Idd9.3), Idd9.1, Idd9.2 and Idd9.3. The incidence of diabetes for
females from these 14 strains at 28 to 30 weeks of age are ,5%
(Idd3/10/18, Idd3/5, Idd3/Idd5.2/Idd5.3 and Idd9), 15–40% (Idd3,
Idd9.1 and Idd5), and 45–65% (Idd5.1, Idd5.2, Idd5.3, Idd5.2/Idd5/
3, Idd9.1, Idd9.2, Idd9.3, and Idd10/18). Throughout the time
period of defining the Idd regions using congenic strains that are
resistant to type 1 diabetes (1990 to 2010) the NOD female
diabetes incidence has ranged from 70–90% at 28 to 30 weeks of
age.
Idd5
Untreated Idd5 mice have a 40% cumulative incidence of
diabetes at 28 to 30 weeks of age [37]. With anti PDL1 treatment,
10-week old Idd5 mice started to develop the disease by day 10,
and after 30 days, 62.5% had developed type 1 diabetes (Figure 1a,
Table 1, 2). The sub-congenic strains Idd5.1, Idd5.2, Idd5.2/5.3
and Idd5.3 showed a faster onset of disease from day 3 to day 7.
The Idd5.3 strain had the highest cumulative incidence of type 1
diabetes following anti PDL1 treatment, with 90% of the mice
developing disease by day 30 (P= 0.0140 Idd5 vs Idd5.3), followed
by Idd5.2 with 80% cumulative incidence (P = 0.0194 Idd5 vs
Idd5.2). Idd5.1 developed diabetes with a 66% cumulative
incidence. The combination of two sub-congenic strains in
Idd5.2/5.3 developed type 1 diabetes with a cumulative incidence
of 65% (Figure 1a, Table 1, 2). Of the control NOD mice treated
with anti PDL1 93% developed type 1 diabetes by day 21. None of
the control NOD mice developed type 1 diabetes during the
course of the experiment (Figure 1a, Table 1, 2).
Idd9, Idd9.1, Idd9.2, Idd9.3
Idd9 mice receiving anti PDL1 treatment developed type 1
diabetes with a cumulative incidence of 46% between days 6 and
16. The sub-congenic strain Idd9.2 showed a reduced cumulative
incidence of diabetes at 56% (between days 4–18), whereas the
Idd9.1 and Idd9.3 strains had a much higher cumulative incidence
with 95% and 90% respectively (onset from day 3 to day 22),
which is quite similar to 93% type 1 diabetes in anti PDL1 treated
NOD mice (between days 4–12) (Figure 1b, Table 1, 2). As the
Idd9.2 strain had the lowest cumulative incidence among Idd9
subcongenic strains, we deduced that this sub-congenic strain must
be associated with the protective allele in the Idd9 congenic
interval.
Idd3, Idd10/18 and Idd3/10/18
Twenty percent of Idd3 mice spontaneously develop type 1
diabetes within 7–8 months [37]. Upon anti PDL1 administration,
50% of the mice developed type 1 diabetes between days 6 and 16
(Figure 1c). Idd10/18 mice have a 50% occurrence of spontaneous
diabetes, and with anti PDL1 treatment 94% of mice developed
the disease between days 4 to 27. The Idd3/10/18 strain develops
diabetes with 31% incidence upon anti PDL1 treatment (days 4 to
28), which is ,6-fold greater than the spontaneous incidence at
the age of 7–8 months (Figure 1c, Table 1, 2).
Idd3/Idd5 and Idd3/5.2/5.3
The Idd3/5 strain has protective alleles at both Idd3 and Idd5
and only 1% of mice develop spontaneous diabetes by 7–8 months
of age [38]. Anti PDL1 treatment did not induce diabetes in Idd3/
5 mice as 100% of them stayed non-diabetic over the course of 30
days PDL1 blockade (Figure 1d). The Idd3/5.2/5.3 (without
protective alleles at the Idd5.1 sub-region) strain that is also almost
completely protected from spontaneous diabetes shows suscepti-
bility to treatment with anti PDL1, and 15% of the mice developed
diabetes by day 30 (Figure 1d, Table 1, 2).
Insulitis in anti PDL1 treated congenic strains
One of the hallmarks of developing type 1 diabetes is the
presence of infiltrating lymphocytes in the pancreas. Idd congenic
strains have made it possible to identify checkpoints of disease
progression. Ninety percent of Idd9 mice show evidence of islet
insulitis, but only 3% develop diabetes spontaneously [21,37].
Analysis of insulitis scores of the Idd strains revealed that NOD
congenics that were partially (Idd 9.2, Idd 3/10/18) or fully (Idd3/
PDL1 Blockade Reverses Genetic Protection from T1D
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5) protected from anti PDL1 accelerated diabetes had lower basal
insulitis scores (Idd 9.2 (0.1860.11), Idd3/10/18 (0.2460.059) and
Idd3/5 (0.060.0) compared to the almost unprotected Idd9.1
(1.260.3), Idd9.3 (0.8260.14) and the NOD (1.2360.24) mice.
These results were statistically significant (Idd9.2 vs Idd9.1, Idd9.3,
NOD p value 0.0016, 0.0031 and 0.0007, respectively; Idd3/10/
18 vs Idd9.1, Idd9.3, NOD p value ,0.0001, 0.0002 and ,0.0001,
respectively; Idd3/5 vs Idd9.1, Idd9.3, NOD p value 0.0047,
0.0014 and 0.0018 respectively).
Clearly, there seems to be a direct link between basal insulitis
levels and the incidence of anti PDL1 induced accelerated
diabetes. Interestingly, Idd9.2 mice that turned diabetic showed
similarly high insulitis scores (3.3160.25) upon anti PDL1
treatment as treated NOD mice (3.25860.1195), while the
Idd9.2 mice which stayed non-diabetic had almost no pancreatic
infiltrates and low insulitis scores (0.3860.17) (Figure 2).
Cytokine and chemokine profile in Idd9 subcongenic
mice
The cumulative incidence of diabetes following anti PDL1
treatment for Idd9.2 was different from that of Idd9.1 and Idd9.3
mice. Nearly 100% of Idd9.1 and Idd9.3 mice while only 56% of
Idd9.2 mice developed type 1 diabetes following anti PDL1
treatment. Basal insulitis was also lower in Idd9.2 versus Idd9.1 and
Idd9.3 mice. Therefore we sought to determine if any cytokines or
chemokines were differentially expressed in these three sub-
congenic lines. Real time PCR of pancreas tissue of anti PDL1
treated mice showed that diabetic Idd9.2 mice had lower
expression of IFN-c, TNF-a, CCR2, RANTES (CCL5) and
MIP-1a (CCL3) as compared to diabetic Idd9.1 and Idd9.3 mice
(Figure 3a-f). MIP-1a up-regulation has been associated with
progression to type 1 diabetes [39]. Idd9 mice also had lower
cytokine and chemokine levels than the Idd9.1 and Idd9.3
substrains. These studies show that a low level of insulitis as
observed in Idd9.2 correlates with lower levels of cytokines even
Figure 1. Incidence of diabetes in NOD congenic mouse strains undergoing anti PDL1 treatment. Treatment was started at 10 weeks of
age. a): Incidence of diabetes in Idd5 and sub-congenics Idd5.1, Idd5.2, Idd5.3 and Idd5.2/5.3 until day 30 after anti PDL1 treatment. In Idd5 mice
(n = 16) 62.5% developed diabetes, in Idd5.1 (n = 15) 66.6%, in Idd5.2 (n = 20) 80%, in Idd5.3 (n = 8) 87.5% and in Idd5.2/5.3 (n = 23) 66.5%. NOD mice
(n = 28) had a 92.5% incidence of diabetes by day 30. All control treated mice did not develop diabetes. b): In Idd9 (n = 26) 46.15% developed
diabetes, in Idd9.1 (n = 20) 95%, in Idd9.2 (n = 30) 56.6% and in Idd9.3 (n = 21) 90.5%. c): Idd3 (n = 17) developed diabetes at a rate of 50%, Idd10/18
(n = 18) at 94.1%, Idd3/10/18 (n = 26) at 30.8%. d): In Idd3/5 (n = 16) 0% of anti - PDL1 treated mice developed diabetes, in Idd3/5.2/5.3 (n = 13) 15.4%.
Statistics and cumulative incidence for the strains are shown in separate Tables for Figure 1. P-values were calculated using Log-rank (Mantel-Cox
test).
doi:10.1371/journal.pone.0089561.g001
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when diabetes develops in some of these mice following PDL1
blockade. It remains to be seen if the quality of insulitis in Idd9 and
Idd9.2 mice is different from that present in the Idd9.1 and Idd9.3
substrains.
Proliferation of BDC2.5 Tg CD4+ T cells and NY8.3 CD8+ T
cells in pancreatic LN of Idd3/10/18 mice following anti
PDL1 treatment
We performed an adoptive transfer of transgenic T cells and
analyzed their proliferation rates to identify differences between
the congenic strains undergoing anti PDL1 blockade. Adoptive
transfer of CFSE-labeled BDC2.5 Tg CD4+ T cells into untreated
NOD and Idd3/10/18 mice showed similar proliferation rates in
the pancreatic LN. With administration of anti PDL1, both NOD
(P= 0.0276) and Idd3/10/18 (P = 0.0002) strains showed signifi-
cantly higher proliferation of BDC2.5 Tg T cells. No difference
was detected in BDC2.5 Tg CD4+ proliferation between untreated
and anti PDL1 treated NOD and Idd3/10/18 mice (Figure 4a, 5a).
In another set of experiments we adoptively transferred CFSE
labeled CD8+ 8.3 TCR Tg+ T cells in Idd3/10/18mice (Figure 4b,
5b) and analyzed their rate of proliferation following anti PDL1
treatment. NY8.3 CD8+ Tg+ T cells divided more frequently as
portrayed by an increase in the number of CFSE-diluted CD8+ T
cells in Idd3/10/18 mice that received anti PDL1 antibody as
compared to mice that received control IgG. These data show that
both auto-reactive CD4 as well as CD8 T cells expand in Idd3/10/
18 mice following anti PDL1 treatment, similar to that of
untreated and anti PDL1 treated NOD mice.
Discussion
More than 38 Idd regions from resistant strains that confer
protection in the NOD model, have been described to date [7,40].
Table 1. Statistical Significance Figure 1.
Comparison of Idd Strains p-value
Idd5 vs. Idd5.1 p=0.1679
Idd5 vs. Idd5.2 p=0.0194
Idd5 vs. Idd5.3 p=0.0140
Idd5.1 vs. Idd5.2/5.3 p = 0.0539
Idd9 vs. Idd9.1 p,0.0001
Idd9 vs. Idd9.2 p=0.2029
Idd9 vs. Idd9.3 p,0.0001
Idd9.2 vs. Idd9.1 p=0.094
Idd9.2 vs. Idd9.3 p=0.0118
Idd3 vs. Idd10/18 p=0.0103
Idd3/10/18 vs. p,0.0001
Idd10/18
Idd3 vs. Idd3/10/18 p=0.2531
Idd3/5 vs Idd3/5.2/5.3 p = 0.2298
doi:10.1371/journal.pone.0089561.t001
Table 2. Spontaneous incidence of type 1 diabetes at 7 months of age compared to anti PDL1 treatment of 10 week old mice.
Strain Line
Cumulative Incidence of
spontaneous type 1 diabetes
Cumulative Incidence of type 1 diabetes with
aPDL1 treatment starting at 10 weeks
NOD.B10-Idd5.1 1094 40% 62.5%
Idd5.2 Idd5.3
NOD.B10-Idd5.1 2193 62% 66%
NOD.B10-Idd5.2 6146 38% 80%
NOD.B10-Idd5.3 6360 69% 90%
NOD.B10-Idd5.2 1595 25% 65%
Idd5.3
NOD.B10- 905 3% 46%
Idd9.1/9.2/9.3
NOD.B10-Idd9.1 1565 35% 95%
NOD.B10-Idd9.2 1566 55% 56%
NOD.B10-Idd9.3 1106 50% 90%
NOD.B6-Idd3 1098 20% 50%
NOD.B6- 7754 50% 94%
Idd10/Idd18
NOD.B6-Idd3/10/18 1538 9% 31%
NOD.B6-Idd3 B10- 6109 1% 0%
Idd5
NOD.B6-Idd3 7380 0% 15%
Idd5.2/5.3
NOD.B6-Idd3 9245 0%
Idd5.2/5.3
NOD 70–90% 93%
doi:10.1371/journal.pone.0089561.t002
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In the current study we examined the effects of 9 Idd regions, alone
and in combination, on accelerated type 1 diabetes following anti
PDL1 treatment. These congenic and subcongenic mice have
multiple protective alleles that mediate varying degrees of
resistance to type 1 diabetes. We chose the NOD Idd congenics
(Idd3/5, Idd9, Idd3/10/18 and Idd3/5.2/5.3) that are almost
completely protected from spontaneous diabetes occurrence due
to allelic interactions between the candidate genes present in the
loci and subloci. We also looked at mouse strains that are
variations of the above-mentioned strains, containing the individ-
ual locus or a combination of loci, where the disease progression is
either moderate (Idd3, Idd9.1, Idd5) or relatively high but always
lower than that of the NOD parental strain (Idd5.1, Idd5.2, Idd5.3,
Idd5.2/5.3, Idd9.1, Idd9.2, Idd9.3, Idd10/18). Frequency of diabetes
in these mice strains range from ,5% to 65%.
PDL1 blockade is known to accelerate diabetes precipitation in
NOD mice. Our aim was to determine if the interaction between
the protective Idd loci in the different NOD congenics affects
diabetes induction by PDL1 blockade. All except one among the
NOD congenic strains tested here, Idd3/5, developed accelerated
type 1 diabetes following anti PDL1 treatment. Our data show
that PDL1 blockade is not enough to induce accelerated diabetes
in the NOD Idd3/5 congenic mice strain that contains alleles for
Il2, Ctla4, Slc11a1 and Acadl. The interaction between these alleles
is able to protect the mice from diabetes induction by PDL1
blockade. We do not observe this in the case of any other congenic
strains. This is probably because Ctla4and Il2both modulate the
survival and function of Treg cell population and the blockade of
PD1-PDL1 pathway is not enough to limit the ability of these
Tregs, and tolerance is maintained in the Idd3/5 congenic mice. It
is also worth mentioning that PDL1 and Ctla4mediated tolerance
induction functions through two distinct pathways. Allelic
interaction of Ctla4 with the other candidate genes in the Idd3/5
strain is able to overcome the effect of anti PDL1 treatment and
maintain tolerance in these congenic mice. Slc11a1 plays an
important part in antigen presenting function of DCs and may
play a role in inducing tolerance to self antigens. Acadl is proposed
to have a significant role in T cell function and survival by altering
fatty acid metabolism. We therefore suggest that the combination
of these four candidate genes and their interaction renders the
Idd3/5 congenics resistant to diabetes induction by PDL1
blockade. The Idd3/5 mice have also been shown to be resistant
to other experimental autoimmunity [41].
The Idd10/18 strain has an insulitis rate of 78%, and ,50%
rate of spontaneous diabetes development [37], in contrast to the
Idd3/10/18 strain which shows greater protection, with 19% of
mice developing insulitis and 7% developing type 1 diabetes. The
Idd3/10/18 strain demonstrates a median protection against anti
PDL1 accelerated diabetes development with a 31% cumulative
incidence as opposed to a cumulative incidence of 94% in Idd10/
18, and 0% in the Idd3/5 strain following treatment. The Idd3/
10/18 strain is almost completely protected from diabetes, similar
to the Idd3/5 strain. However, the effect of PDL1 blockade results
in significantly different outcomes in respect to diabetes induction.
These data also imply that in the absence of negative costimulation
by the PD1-PDL1 pathway, CTLA4 possibly maintains the self
tolerance with the help of IL-2 (one of the candidate genes in Idd3)
in case of the Idd3/5 strain. And IL-2 alone is not sufficient to
prevent anti PDL1 mediated accelerated diabetes in case of the
Idd3/10/18 strain. Similarly in Idd3/5.2 and Idd3/5.3 strains
where the congenic Idd5.1 locus containing the CTLA4 gene is
absent, IL-2 alone cannot prevent diabetes induced by PDL1
blockade.
The Idd9 strain including sub-congenic 9.1, 9.2 and 9.3 shows
high levels of pancreatic infiltrates (90%), but does not develop
diabetes at a high rate (3%) [21]. Nonetheless, this strain develops
insulin autoantibodies [27]. The Idd9.1 region was identified to
control type 1 diabetes development through TNF-a [42]. Idd9.2
and Idd9.3 regions were found to be responsible for preventing the
expansion of islet specific CD8+ T cells, providing an explanation
for the dichotomy of high insulitis incidence and a low rate of
actual diabetes development in the Idd9 strain [24].
Remarkably, a profound increase of diabetes incidence (3% to
50%) was observed after PDL1 blockade in Idd9 congenic mice.
We studied the effect of anti PDL1 on Idd9 subcongenics (Idd9.1,
Idd9.2 and Idd9.3). Interestingly, almost 100% of Idd9.1 and Idd9.3
mice developed accelerated diabetes following anti PDL1 treat-
ment, in contrast to the Idd9.2 strain, which was partially protected
(56% became diabetic). Findings in the Idd9 strain suggest that in
mice that already have infiltrating lymphocytes in target organs at
10 weeks of age, like Idd9.1 and Idd9.3 strains, diabetes
development is exacerbated following anti PDL1 treatment.
Idd9.1 and Idd9.3 strains which develop accelerated diabetes, also
show slightly higher scores of insulitis. Idd9.2 mice had significantly
less pancreatic infiltrates and only 56% developed diabetes after
anti PDL1 treatment.
The Idd9 mice strain similar to Idd3/5 and Idd3/10/18, is also
resistant to spontaneous diabetes occurrence. However, the level of
insulitis is much higher in the Idd9 strain in comparison to that of
Idd3/5 and Idd3/10/18. The difference in the pathogenicity of the
Figure 2. Insulitis scores in anti PDL1 treated mice. Idd congenic
mice were grouped into control treated (untx, white columns, Idd9.1
n= 7, Idd9.2 n= 10, Idd9.3 n=9, Idd3 n= 4, Idd10/18 n= 5, Idd3/10/18
n= 18, Idd3/5 n= 3, NOD n=7), anti PDL1 treated diabetic (Tx-D,
checked columns, Idd9.2 n= 4, Idd3 n=5, Idd10/18 n=8, Idd3/10/18
n= 6, NOD n= 11) and anti PDL1 treated non-diabetic (Tx-ND, black
columns, Idd9.2 n=5, Idd3 n=5, Idd10/18 n= 1#, Idd3/10/18 n=6, Idd3/
5 n= 17) mice. The antibody treatment was given to 10-week old mice
at day 0 (500 mg), and days 2, 4, 6, 8 and 10 (250 mg). The injections
were stopped once the mouse had become diabetic and had a glucose
reading of .250 mg/dl on two consecutive days. H&E sections of
pancreases were scored for degree of infiltrating lymphocytes in islets.
Results are expressed as Mean6SD. P-values are expressed as * (P,
0.05), ** (P,0.01), *** (P,0.0001). # In case of the Idd10/18 mice,
treatment with anti PDL1 resulted in 94% of diabetes incidence.
Therefore, it was extremely difficult to increase the n of anti PDL1
treated non-diabetic group.
doi:10.1371/journal.pone.0089561.g002
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disease in the Idd9 strain is attributed to the Th2 type cellular
response induced by the TNFR superfamily gene cluster present in
the Idd9 locus. The combination of three sub loci Idd9.1, Idd9.2
and Idd 9.3 renders this strain resistant to the disease even though
individually the candidate genes are susceptible. PDL1 blockade
negates this interaction and in the absence of any other functional
negative costimulatory pathway, disease progression is accelerated
and pathogenicity is altered. Among the three subloci of Idd9,
Idd9.2 is considered the most potent region in providing protection
against the disease by restraining autoreactive CD8+ T cells.
Blockade of PDL1 is known to cause CD8+ T cell exhaustion. This
explains the similarity in the anti PDL1 induced diabetes incidence
(approximately 50%) in the Idd9 and Idd9.2 strains; whereas the
Idd9.1 and Idd9.3 strains are completely susceptible (90-95%) to
anti PDL1 induced diabetes. We also observe a very low frequency
of pancreatic infiltrates in the Idd9.2 strain. This can be explained
by the fact that the strains of Idd9 and its sub regions have a low
frequency of autoreactive CD8+ T cells in comparison to the NOD
mice. Further, the genes in the Idd9 sub regions prevent a massive
expansion of these autoreactive CD8+ T cells during disease onset
and progression [25]. However, extensive insulitis was observed in
the group of Idd9.2 mice that become diabetic after PDL1
blockade suggesting that in some of the mice the low frequency of
autoreactive cells can expand when this regulatory pathway is
inhibited. The decreased cytokine and chemokine production in
Idd9 and Idd9.2 mice may also be related to the low frequency of
autoreactive T cells [25] that affects the quality of the infiltrating
cells following PDL1 blockade as compared to mice not having
protective alleles at Idd9.2.
Our study using treatment with anti PDL1 mAb indicates that
sufficient numbers of effector cells are present in these congenic
strains to mediate type 1 diabetes. The rapid onset of diabetes in
some of the Idd congenic strains is probably due to auto-aggressive
memory/effector T cells that are suddenly set free when PDL1 is
blocked, as has been shown in a study in NOD mice [43].
Further, CD4+ Type II NKT cells were shown as regulators of
diabetes and it was shown that these cells were sufficient in down-
regulating diabetes, promoting activity of CD4+ BDC2.5 tg T cells
in vivo. Interestingly, blockade of ICOS and PDL1 was found to
negate the regulatory effect of the CD4+ Type II NKT cells in the
pancreatic lymph node leading to a sudden development of
diabetes [44].
We used the Idd3/10/18 strain to further dissect anti PDL1
mediated diabetes. BDC2.5 Tg CD4+ T cells were transferred into
NOD and Idd3/10/18 mice treated with anti PDL1. Similar rates
of T cell proliferation were observed in pancreatic LNs of both
strains. Corresponding to CD4+ TCR Tg T cells tested above,
CD8+ 8.3 TCR Tg+ T cells divided more frequently, as seen by an
increase in the number of CFSE-diluted CD8+ T cells in Idd3/10/
18 mice (and NOD mice) that received anti PDL1 antibody as
compared to mice that received control IgG. These data are
similar to our findings in regular NOD mice [4] and suggest that
Figure 3. Quantitative PCR detection of cytokine, chemokine and transcription factor levels in pancreas tissue after anti PDL1
treatment in Idd9 (n =3) and subcongenics Idd9.1(n =3), Idd9.2 (n =5), Idd9.3 (n =5). Mice (10 weeks old) were treated with 500 mg anti PDL1
on day 0 and 250 mg anti PDL1 on days 2, 4, 6, 8 and 10 by i.p. injection. Pancreas tissue was harvested on day 30 or when mice had turned diabetic.
Horizontal lines show median value. P-values are expressed as * (P,0.05), ** (P,0.01), *** (P,0.0001) in figure. a): IFN-c: Idd9.1 vs. Idd9.2 p= 0.0039;
Idd9.1 vs. Idd9.3 p= 0.063. b): CCR2: Idd9 vs. Idd9.1 p=0.0003; Idd9.1 vs. Idd9.2 p,0.0001; Idd9.2 vs. Idd9.3 p=0.0431; Idd9 vs. Idd9.3 p=0.0183. c):
RANTES: Idd9 vs. Idd9.1 p= 0.022; Idd9.1 vs. Idd9.2 p=0.0016; Idd9.2 vs. Idd9.3 p= 0.0284; Idd9 vs. Idd9.3 p= 0.0382. d): No significant differences in
FoxP3 expression between Idd9 and subcongenics. e): MIP-1a: Idd9 vs. Idd9.1 p= 0.0257; Idd9.2 vs. Idd9.1 p= 0.0017. f): TNF-a:Idd9 vs. Idd9.1 p=0.019;
Idd9.2 vs. Idd9.1 p=0.0004.
doi:10.1371/journal.pone.0089561.g003
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the lower susceptibility of Idd3/10/18 mice to develop type 1
diabetes following PDL1 blockade is probably not dependent on
expansion of CD4 and CD8 T cells, rather that anti PDL1
treatment likely affects behavior of these cells which contributes to
lowering susceptibility for developing disease. The role of PDL1
expression in the pancreas and its effect on resistance in this strain
remains to be further investigated.
Correlation between the level of basal insulitis and the
development of anti PDL1 induced diabetes also proved to be
true in the case of Idd3/5 mice to which anti PDL1 was
administered. These mice stayed diabetes free. The Idd3/5 strain
exhibits profound resistance, has the lowest spontaneous diabetes
incidence, and also shows the lowest levels of insulitis among all Idd
congenics.
Prominent genes associated with Idd3/5 congenic strain are Il2
and Il21 from Idd3, and Ctla4 from Idd5 regions [37]. The role of
IL-2 in diabetes has been previously demonstrated. NOD mice
express less IL-2 than diabetes resistant mouse strains [45], and
low dose IL-2 administered at the onset of type 1 diabetes can
reverse established disease in NOD mice [46]. This mechanism
has been attributed to an increase in regulatory T cell numbers in
the pancreas, and to increased expression of FoxP3, CD25,
CTLA-4, ICOS and GITR [46]. Lower levels of IL-2 were found
to have an impact on antigen presenting cells like DCs, since low
IL-2 levels correlated with higher numbers of DCs and increased
T cell stimulation and activation. The cellular mechanism of
protection from T1D in Idd3/5 congenic mice strain is already
defined by Hamilton-Williams et al. [9].
Further analysis of the Idd3/5 region showed that removal of
protective alleles at a subcongenic region from the Idd3/5 region
as in the Idd3/5.2/5.3 strain results in a 15% incidence of disease
upon anti PDL1 treatment in contrast to no incidence of disease in
the Idd3/5 group, which supports the role of Ctla4 at the Idd5.1
locus in preventing diabetes in a concerted interplay with Idd3.
Although Idd3/5.2/5.3 mice do not develop diabetes, an increase
of insulitis in Idd3/5.2/5.3 mice as compared to Idd3/5 has been
reported [33]. These observations support the hypothesis that the
ability of PDL1 to accelerate diabetes relies on some minimal
amount of effector cell accumulation that is normally manifested
as at least a mild insulitis.
Conclusion
Taken together, our data show that PDL1 blockade destroys the
genetic protection mediated by different protective alleles. We
show a link between occurrence of insulitis and disease suscepti-
bility through a break of tolerance induced by anti PDL1. We
suggest that the presence of a functional CTLA4 allele is probably
Figure 4. Proliferation of adoptively transferred BDC2.5 Tg CD4 T and NY8.3 tg CD8+ T cells in pancreatic LN and spleen of anti
PDL1 treated NOD and Idd3/10/18 mice. A) Representative CFSE dilution plot for each group is shown. Cells were gated on CD4+ Vbeta 4+. B) A
representative CFSE dilution plot of transferred NY8.3tg T cells for each group is shown. Cells were gated on CD8+ Vbeta 8+.
doi:10.1371/journal.pone.0089561.g004
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responsible to prevent disease susceptibility induced by anti PDL1.
Increased understanding of the mechanisms of gene-gene interac-
tion, and discovering additional traits that play a role in type 1
diabetes will help identify novel treatments of this disease. The
PD1-PDL1 pathway is currently studied for developing therapy for
cancer and infectious diseases including HIV, since blockade of
this pathway results in increased immune responses against tumor
cells [1,47,48] and infectious agents [3,49,50]. However, we show
that blockade of this pathway interrupts critical tolerance
mechanisms that operate to prevent autoimmune diabetes.
Acceleration of diabetes following PD1-PDL1 pathway blockade
to treat disease underscores the need for caution before proceeding
to a widespread use of this form of treatment, especially when used
in combination with antiCTLA-4 (Ipilimumab) that is currently
approved for use in melanoma. A combined blockade of CTLA4
and PD1-PDL1 will in all probability shift the balance from an
effective immune response towards autoimmunity. It is important
to note that our group had earlier shown that type 1 diabetes
resistant NOR mice, which are congenic for the MHC locus to the
NOD mice, did not develop diabetes following anti PDL1
treatment [51]. The fact that these congenic mice were protected
against type 1 diabetes post-anti PDL1 treatment suggests that
PDL1 blockade may still prove suitable in human patients without
HLA alleles associated with autoimmune disease such as type 1
diabetes.
Future research should focus on strategies to exploit enhanced
immune responses by blocking the PD-PDL1 pathway and at the
same time prevent the development of autoimmune disease as a
consequence.
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Figure 5. Proliferation of adoptively transferred BDC2.5 Tg CD4 T and NY8.3 tg CD8+ T cells in pancreatic LN and spleen of anti
PDL1 treated NOD and Idd3/10/18mice. a) Collective data from 3 out of 8 experiments of the percentage of CFSE-dividing cells (gated on CD4+
Vb4+) are shown. Horizontal lines express mean value. For CD4+ T cells pLN, NOD, control vs. treated p= 0.0276; pLN, Idd3/10/18, control vs. treated
p= 0.0002. b) A representative experiment from 3 performed is shown. For CD8 T cells pLN, Idd3/10/18 control vs. treated p= 0.0321, spleen Idd3/10/
18 control vs. treated p=0.0185.
doi:10.1371/journal.pone.0089561.g005
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